The cancer cell-derived extracellular vesicle glycocode in immunoevasion

Jenifer P Goncalves; Vatsal J Deliwala; Daniel Kolarich; Fernando Souza-Fonseca-Guimaraes; Joy Wolfram

doi:10.1016/j.it.2022.09.004

The cancer cell-derived extracellular vesicle glycocode in immunoevasion

Trends Immunol. 2022 Nov;43(11):864-867. doi: 10.1016/j.it.2022.09.004. Epub 2022 Oct 13.

Authors

Jenifer P Goncalves¹, Vatsal J Deliwala¹, Daniel Kolarich², Fernando Souza-Fonseca-Guimaraes³, Joy Wolfram⁴

Affiliations

¹ Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Building 75, Cnr College Rd & Cooper Rd, St Lucia, QLD 4072, Australia.
² Institute for Glycomics, Griffith University, Parklands Dr Southport, Gold Coast, QLD 4222, Australia. Electronic address: d.kolarich@griffith.edu.au.
³ Diamantina Institute, The University of Queensland, 37 Kent St, Woolloongabba, QLD 4102, Australia. Electronic address: f.guimaraes@uq.edu.au.
⁴ Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Building 75, Cnr College Rd & Cooper Rd, St Lucia, QLD 4072, Australia; School of Chemical Engineering, The University of Queensland, Andrew N. Liveris Building, 46 Staff House Rd, St Lucia, QLD 4072, Australia. Electronic address: j.wolfram@uq.edu.au.

PMID: 36244891
DOI: 10.1016/j.it.2022.09.004

Abstract

Recent evidence suggests that cancer cell-derived extracellular vesicles might facilitate immunoevasion. Glycans are known to play a key role in immunomodulation, especially when tethered to biological membranes. However, the extracellular vesicle glycocode in cancer immunoevasion remains a largely unexplored area with promising potential for new putative diagnostic and therapeutic applications.

Keywords: cancer; exosome; extracellular vesicle; glycomics; immunosuppression; microvesicle.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Extracellular Vesicles*
Humans
Neoplasms* / therapy